chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Received Tdap right deltoid 7/13/15, 7/14/15 noticed swelling and redness to right deltoid, MD diagnosed with antigenic cyst and given KEFLEX 250 mg.
At 24 hours, redness, swelling of left arm deltoid with 4.5 diameter. At 48 hours, less redness and swelling of the area. At 72 hours, rash all over body given Benadryl
Very tight chest; Radiatiing pain in left side of jaw; Concerned about heart attack; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 68 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 02Oct2021 12:15 (Lot number: WAG 9048) at the age of 68 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Barrett's esophagus" (unspecified if ongoing); "High BP" (unspecified if ongoing), notes: Verbatim: High BP; "Anemia" (unspecified if ongoing); "Hypothyroidism" (unspecified if ongoing); "known allergies : antibiotics" (unspecified if ongoing), notes: known allergies : antibiotics. Concomitant medication(s) included: IRON; SYNTHROID; HYZAAR; OMEPRAZOLE; LIPITOR. Past drug history included: Morphine, reaction(s): "known_allergies: Morphine". Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: EP6955, Location of injection: Arm Left, Route of administration: Intramuscular), administration date: 09Mar2021, when the patient was 67 years old, for COVID-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: EN6200, Location of injection: Arm Left, Route of administration: Intramuscular), administration date: 16Feb2021, when the patient was 67 years old, for COVID-19 immunization. The following information was reported: CHEST DISCOMFORT (non-serious) with onset 04Oct2021, outcome "unknown", described as "Very tight chest"; PAIN IN JAW (non-serious) with onset 04Oct2021, outcome "unknown", described as "Radiatiing pain in left side of jaw"; ANXIETY (non-serious) with onset 04Oct2021, outcome "unknown", described as "Concerned about heart attack". The events "very tight chest" and "concerned about heart attack" were evaluated at the emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of chest discomfort, pain in jaw, anxiety.  Additional information: Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested positive for COVID-19. The patient did not receive other vaccine in four weeks. 2 days after 3rd dose patient had a very tight chest with some pain radiating her left jaw - after breakfast. She ate a 325 aspirin after 40 mints the pain started.  No follow-up attempts are possible. No further information is expected.  Follow-up PRD/SRD (15Nov2021) Follow-up attempts completed. No further information expected.
PATIENT INDICATED SIGNS OF UNSUAL BLEEDING (PURPURA) ON BOTH OF HIS ARMS AFTER I HAD GIVEN HIM HIS SECOND DOSE OF THE MODERNA COVID 19 VACCINE.  SINCE HE HAD NO PREVIOUS HISTORY OF ANY CHRONIC ILLNESS OR ON ANY MEDICATION, ALSO HE HAD NOT BUMPED INTO ANY OBJECT BY ACCIDENT.
When I caught COVID-19 it started with a scratchy throat. Then I had a headache and then an actual sore throat. I never had a fever. I was very tired. I had a migraine headache. I had a cough, and I still have it currently. I am occasionally having migraines as well. I took TYLENOL.
Headache, Myalgia, Fever, sore right arm Narrative:   Other Relevant History:
Itching near ribcage, left and right; raised/lumpy rash all over the body; Itching on the back; Rash all over his body (upper to lower body); This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PRURITUS (Itching near ribcage, left and right), RASH (raised/lumpy rash all over the body), PRURITUS (Itching on the back) and RASH (Rash all over his body (upper to lower body)) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, the patient experienced PRURITUS (Itching near ribcage, left and right), RASH (raised/lumpy rash all over the body), PRURITUS (Itching on the back) and RASH (Rash all over his body (upper to lower body)). The patient was treated with CORTISONE at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. On 18-Feb-2021, PRURITUS (Itching near ribcage, left and right) had resolved. At the time of the report, RASH (raised/lumpy rash all over the body), PRURITUS (Itching on the back) and RASH (Rash all over his body (upper to lower body)) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Diarrhea if becomes anxious or nervous; Diarrhea if becomes anxious or nervous; Chest tightness; Diarrhea if becomes anxious or nervous; Patient received first dose on 30-Mar-2021 and second dose on 20-Apr-2021; Sore arm with Covid vaccines; This spontaneous case was reported by a consumer and describes the occurrence of ANXIETY (Diarrhea if becomes anxious or nervous), NERVOUSNESS (Diarrhea if becomes anxious or nervous), CHEST DISCOMFORT (Chest tightness), DIARRHOEA (Diarrhea if becomes anxious or nervous) and PAIN IN EXTREMITY (Sore arm with Covid vaccines) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    No Medical History information was reported.   On 30-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to at an unspecified dose. On 20-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received first dose on 30-Mar-2021 and second dose on 20-Apr-2021). In 2021, the patient experienced PAIN IN EXTREMITY (Sore arm with Covid vaccines). On an unknown date, the patient experienced ANXIETY (Diarrhea if becomes anxious or nervous), NERVOUSNESS (Diarrhea if becomes anxious or nervous), CHEST DISCOMFORT (Chest tightness) and DIARRHOEA (Diarrhea if becomes anxious or nervous). At the time of the report, ANXIETY (Diarrhea if becomes anxious or nervous), NERVOUSNESS (Diarrhea if becomes anxious or nervous), CHEST DISCOMFORT (Chest tightness), DIARRHOEA (Diarrhea if becomes anxious or nervous), PAIN IN EXTREMITY (Sore arm with Covid vaccines) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received first dose on 30-Mar-2021 and second dose on 20-Apr-2021) outcome was unknown.            Concomitant product use was not provided by the reporter.  It was unknown if patient was enrolled in a COVID-19 vaccine trial.   The reporter's causality with Humira for the events of sore arm with COVID vaccines, diarrhea if becomes anxious or nervous and chest tightness was not provided.  No treatment information was provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   This case was linked to MOD-2022-624775 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 20-Jan-2022: Additional follow up received, added event of chest tightness.
Severe allergic reaction with fever; Chronic issues got worse; rash; fever; fatigue; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (Severe allergic reaction with fever), CONDITION AGGRAVATED (Chronic issues got worse), RASH (rash), PYREXIA (fever) and FATIGUE (fatigue) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced HYPERSENSITIVITY (Severe allergic reaction with fever), CONDITION AGGRAVATED (Chronic issues got worse), RASH (rash), PYREXIA (fever) and FATIGUE (fatigue). At the time of the report, HYPERSENSITIVITY (Severe allergic reaction with fever), CONDITION AGGRAVATED (Chronic issues got worse), RASH (rash), PYREXIA (fever) and FATIGUE (fatigue) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   The patient did not receive any treatment for the events.
After patient received this vaccine and BICILLIN, the patient was eating lunch in a chair and stiff with witness convulsions. After placing the patient on the floor he was alert and oriented with slow responses and movement. He stated it was default for him to move. Transfer to hospital for further evaluation.
KINRIX & VARICELLA vaccine given into (R) arm 4x4 cm area of erythema and 9x7 cm area of erythema surrounding injection site to: Septra
Admitted to the hospital with nausea and AMS as well as generalized weakness and acute metabolic encephalopathy. Positive for Covid. Treated with decadron, CRP and D dimer were elevated. Discharged on eliquis as Covid VTE ppx
This case was reported by a other health professional via sales rep and described the occurrence of adverse reaction in a female patient who received SHINGRIX for prophylaxis. In May 2018, the patient received SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced adverse reaction and pain in arm. The patient was treated with Antibiotic (Drug Name Unknown). On an unknown date, the outcome of the adverse reaction and pain in arm were unknown. It was unknown if the reporter considered the adverse reaction and pain in arm to be related to SHINGRIX. Additional details were provided as follows: The age at the vaccination was not reported. The reporter only stated that a patient had a bad reaction and had to be put on antibiotics. The patient had pain that would not go away around the arm. The patient might had received the injection in May 2018 based when the reporter spoke with the reporter saying it was a month ago when he was told about in June 2018. There were no specifics given to the sales representative. The sales representative was a new employee and was not aware that adverse events were required to be reported within 24 hours of acknowledgement and the type of information at a minimum to ask when he heard an adverse event.
Discharge Provider: MD Primary Care Provider: MD Admission Date: 7/29/2022 Discharge Date: Aug 11, 2022  PRESENTING PROBLEM: Acute abdominal pain  Enteritis Ischemic bowel disease Small bowel ischemia Volvulus   HOSPITAL COURSE: Patient is a 94Y female with PMH of CHF, coronary artery disease, hypertension, GERD, and AFib on Eliquis who presented with severe abdominal pain.  CT scan was concerning for possible bowel ischemia.  Originally admitted to Medicine, was made NPO and given maintenance IV fluids for bowel rest.  Started on prophylactic Zosyn.  Incidentally, patient was also found to be COVID positive.  Serial abdominal exams were done and progressed to having peritoneal signs on exam.  Extensive discussions were had with patient and family and they decided they wanted to pursue surgery despite risks.  She was taken for exploratory laparotomy on 07/30, and had an ileocecectomy with primary anastomosis.  Postoperatively, pain was well controlled and patient was given supportive care while we awaited bowel function.  Overnight on 08/01, patient was transferred to the SICU due to being hypotension and oliguria.  While in the unit, patient underwent ongoing resuscitation and supportive cares.  Patient started having bloody stools with a stable hemoglobin, decision was made to stop Eliquis indefinitely.  Likely bleeding from anastomosis but not requiring urgent intervention.  Patient was transferred out of the intensive care unit to a facility.  Diet was advanced as tolerated, up to a postsurgical soft diet which she tolerated well.  Notably patient also developed pleural effusions, that required IR drainage.  Prior to discharge pain was well controlled, patient was having bowel function, denied any trouble breathing, and was having no other acute issues.  Patient was discharged in stable condition to SAR.
Patient passed out after receiving Tdap and MENACTRA. She passed out for 2 minutes after receiving shots.
On the day my symptoms started, I had face pain through the tops of my cheeks and my jaw and a congested nose. The following day when I woke up, I had a bad cough that produced a green/yellow mucus, body aches through my chest and shoulders, runny nose, congestion, sneezing, difficulty breathing, and fatigue. I went to my local urgent care because my primary care doctor's office was closed. I was diagnosed with bronchitis. I was prescribed ten 20mg tablets of prednisone and six 250mg tablets of zithromax z-pack. After finishing both prescriptions, I still have a slight cough which occasionally produces clear mucus and an occasional runny nose.
Fever of 101.7, chills starting at night. Headache. Muscle and joint aches. Arm and shoulder soreness near injection site.
Recurring low grade fever between 99.5-100.5 for several days after 2nd dose.   Achiness, chills, and headache the first 48 hours after 2nd dose, but fever keeps recurring for 5 days after injection.
near syncope 5 minutes after vacccination. 10:20-feeling "hot", skin clammy, dizziness 10:23-diaphoretic, clammy, pale coloring, lightheadedness, BP 60/40, P-50, R-12 sitting in chair without talking, but able to respond non-verbally, 10:28- BP 80/40 P-56, R-16 severe dizziness, pallor continues, diaphoretic, 10:35- BP 102/68, P-64, R- 20 color returning to body, dizziness subsiding,  10:45- BP 110/76 P-76, R-20 skin dry, patient talking and reports feeling better, dizziness subsided, color back to baseline,  10:55- BP 108/70, P-88, R-20 pt back to pre-vaccination baseline, ambulated in hallway x 2 with PHN without return of symptoms, discharged to self care
Approx 3 -5 minutes after vaccine -redness and hives on both arms, chest, and face. Approximately 10 minutes after vaccine- cough, shortness of breath, tongue itchy, lips swelling. Epi pen in L thigh, 50 mg benedryl IM in R deltoid. Brought to emergency room, 1 liter normal saline, pepcid, solu-medrol, 25mg benadryl IV. D/c to home around noon. 1/22/2020- secondary anaphylactic reaction at 945am. Epi pen to r thigh, 50mg PO benadryl, 20mg prednisone. Drove to hospital ER received 1 liter of normal saline, pepcid, 25mg benadryl IV, 40mg prednisone. D/C at 3pm on prednisone taper.
bad cold type symptoms; Fever; COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 23Oct2021 at 12:45 as dose 3 (booster), single (Lot number: EW0187) at the age of 66 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "High blood pressure" (unspecified if ongoing); "Known allergies: Penicillin" (unspecified if ongoing); "Depression" (unspecified if ongoing); "Overweight" (unspecified if ongoing); "Low thyroid" (unspecified if ongoing). Concomitant medication(s) included: LEVOTHYROXIN, start date: 01May1994; HYDROCHLOROTHIAZIDE, start date: 30Aug2019; LOSARTIN, start date: 30Aug2019; FLUOXETINE, start date: 17May2012; NYQUIL, start date: 26Apr2022; PEPTO-BISMOL, start date: 28Apr2022; ROBITUSSIN [AMYLMETACRESOL;DICHLOROBENZYL ALCOHOL], start date: 05Apr2022, stop date: 05Apr2022. The following information was reported: PYREXIA (non-serious) with onset 08May2022, outcome "recovered" (08May2022), described as "Fever"; NASOPHARYNGITIS (non-serious) with onset 08May2022 at 12:00, outcome "not recovered", described as "bad cold type symptoms"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset May2022, outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (May2022) Negative; (May2022) Negative; (May2022) Negative; (May2022) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19. Therapeutic measures were not taken as a result of nasopharyngitis, pyrexia.  Clinical information: The patient was taking other medications/products within 2 weeks of starting COVID-19 treatment. The patient previously receive a COVID-19 Vaccine. A bad cold type symptoms returned after about 7 days of feeling better. And 3 negative tests. A fever came and went on 08May. Adverse event start date: 08May2022. Adverse event start time: 12:00 PM. Patient start treatment with Paxlovid (From 29Apr2022 to 03May2022).  No follow-up attempts are needed. No further information is expected.
Anaphylaxis onset >6 hrs; 3 convuls p/immun-coma or marked alteration in level of consciousness during sz; had apnea @home w/cyanosis @that time; had twitching of rt arm; sz in hosp w/lateral gaze, cyanosis & postictal phase w/lethargy;
Approximately four hours after immunization given, pt was noted to become weak and listless by school teacher. Pt then began drooling and having left sided seizure activity, including arm twitching and both eyes twitching. The events lasted approximately three minutes. pt complained of fatigue and frontal headache after episode and vomited once. Of note, pts father has history of seizures.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. No information was provided regarding concurrent conditions, medical history, or concomitant medications. On or about 29-JAN-2007, a healthcare provider at a medical facility administered ZOSTAVAX to the patient to obtain permanent prevention and protection against shingles and zoster-related injuries/conditions (dose, route, and lot # not provided). On or about 26-DEC-2014, the patient was treated by a healthcare professional at the same medical center for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of ZOSTAVAX, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was not recovered. Causality assessment was related. Additional information has been requested.
13AUG 10-11PM t105, lifeless & white; 15AUG ER, fussy, t103.5, dx pneumonia; given meds, prescription never filled;
Hiccups for 2 days after vaccination; This is a spontaneous report from a contactable consumer. An adult male patient of unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. It was not reported if the patient received any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. On an unknown date the patient experienced hiccups for two days after vaccination. The clinical outcome of the event hiccups or two days after vaccination was resolved on an unknown date.   The lot number for BNT162b2 was not provided and will be requested during follow up.
5/15/07 Child came in for well child exam visit; receiving Varicella and HPV vaccine. 5/17/07: Doctor visit progress notes read as follows: immunization 2 days ago, HPV and Varicella. Sibling also here with similar reaction. Temp 97.2F. Physical examination: 1/2 dollar sized area of induration and erythema left arm at injection site. Adv- Benadryl, rech prn.
On 1/30,  I began experiencing a red rash, very itchy, painful to the touch, firmer and slightly swollen than the surrounding area, five inches across since onset. Treated with ice. Symptoms are ongoing. Doctor notified on 1/31.
the day following vax pt devel fever 103.6f & non-pruritic rash consisting of tiny red bumps on face & chest plus dry, nonproductive cough. addl info requested
This case was reported by a physician (also subject) and described the occurrence of myelitis in an adult female subject who was vaccinated with HAVRIX (GlaxoSmithKline). Concurrent medical conditions included foreign travel. Concurrent vaccination included typhoid vaccine (non-gsk); non-GSK manufacturer; unknown given on 9 November 2013. On 9 January 2013 the subject received a dose of HAVRIX (unknown details). On 19 January 2013, 10 days after vaccination with HAVRIX, the subject experienced myelitis. The physician stated that she was "recently diagnosed with myelitis probably due to the vaccine I got before" travel. This case was assessed as medically serious by GSK. At the time of reporting the outcome of the event was unspecified. The physician considered the event was probably related to vaccination with HAVRIX.
Invalid dosing interval between dose 1 and dose 2; This non-serious case was reported by a nurse and described the occurrence of drug dose administration interval too short in a female patient who received Men B NVS (Bexsero) for prophylaxis.   Concomitant products included MENINGOCOCCAL VACCINE B RFHBP/NADA/NHBA OMV (BEXSERO).   On 13-JUL-2023, the patient received the 2nd dose of Bexsero. On 13-JUL-2023, an unknown time after receiving Bexsero, the patient experienced drug dose administration interval too short (Verbatim: Invalid dosing interval between dose 1 and dose 2). The outcome of the drug dose administration interval too short was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 26-Jul-2023 The patient received dose 1 on June 29 2023 and dose 2 on July 13 2023, which led to shortening of vaccination schedule. The health care professional (HCP) did not consent to follow up.
mild urticaria immediately post vaccine, then for several weeks after, tachycardia and weight loss
Patient claimed her arm was sore and had a bump where she received the vaccine. Patient has very small arms and the pharmacist used a 5/8inch needle.
Nausea, headache, body aches. Drank some ginger tea. Lasted until 3/27/2015. Felt sick and crummy.